Opus Genetics outlines five gene therapy programs for retinal diseases
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/17/2026
- Wall St rises as oil slide offers respite after Fed rate hike
- Oil falls 2% to one-week low as Middle East supply disruption fears ease
- The Fed is hiking. Why isn't UBS worried about stocks?
- Wall Street on Fed rate hike: 'As hawkish as it gets'
- RBC bullish on Kraft Heinz, sees return to growth in 2027
- Generac strikes $8B supply deal with Amazon for data center power
- Wall St ends lower after Fed hikes interest rates, sees more tightening ahead
- Shipping stocks on fire — but cracks are forming in the rate rally
- JPMorgan Fed scenario analysis: 5 paths for the S&P 500 today
- Paradium AI (PAAI) Halted, News Pending
Opus Genetics Highlights Five Gene Therapy Programs Targeting Significant Unmet Need in Patients with Inherited Retinal Diseases
June 16, 2026 4:05 PM EDTRapidly Advancing Five IRD Programs with Four Clinical Data Readouts Expected in 2027
RDH12, MERTK and RHO Programs Expected to Enter Clinical Testing over the Next 12 to 18 Months
Cash Runway into 2029 Expected to Fund Multiple Clinical Inflection Points, Potential Product Approvals and Opportunities for Priority Review Vouchers
IRD Prevalence Across Select Global Markets Provides a Significant Commercial Opportunity Across Opus Genetics Pipeline
RESEARCH TRIANGLE PARK, N.C., June 16, 2026 (GLOBE NEWSWIRE) --... More
